NYSE$IBIO
iBio Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
iBio's financial results for the fiscal quarter ended December 31, 2021 were reported.
iBio reported a decrease in revenue and an increase in net loss for the second quarter ended December 31, 2021. The company is focusing on advancing its pipeline and platform technologies while managing cash effectively.
- Added six new immuno-oncology assets to the pipeline in the last six months.
- Advanced a new asset into late-discovery stage using artificial intelligence design capabilities.
- Exploring the use of a novel peptide with anti-fibrotic effects in treating solid tumors.
- Prepared to move the second-generation COVID-19 vaccine candidate towards the clinic.
Headline financials
Revenue & EPS history
iBio · Revenue · Quarterly
$168K
Forward guidance
iBio expects revenue growth to return in the second half of fiscal 2022 and believes it has adequate cash to support its activities through September 30, 2023.
Tailwinds
- Revenue growth expected to return in the second half of fiscal 2022.
- Adequate cash to support activities through September 30, 2023.
- Advancing IBIO-202 and other key Biopharmaceutical and Bioprocess initiatives.
- Continuing to advance its IL-2 sparing anti-CD25 antibody, IBIO-101, and moving the program from the Lead Optimization to IND-Enabling stage before the middle of calendar 2022.
- Initial data from the collaboration with the University of Texas Southwestern Medical Center expected in the second half of calendar 2022.
Headwinds
- Significant quarter-to-quarter revenue variability.
- R&D and G&A expenses increased over the comparable period in fiscal 2020.
- Net loss increased compared to the same period in 2020.
- Deferring a number of planned new hires.
- Less aggressively advancing the IBIO-100 program.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-1.4%
Avg return
Earnings day
-2.9%
Avg return
5 days after
+14.3%
Avg return
30 days after
43%
17 / 40 earnings
Positive
+24.4%
Q3 2020
Best reaction
-34.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +12.9% | +9.9% | +22.8% | |
| Q1 2026 | -8.0% | -3.2% | +55.2% | |
| Q4 2025 | +3.7% | +8.6% | +6.2% | |
| Q3 2025 | +1.3% | +1.3% | +30.4% | |
| Q2 2025 | -14.8% | -7.8% | +49.2% | |
| Q1 2025 | -9.4% | -10.9% | -2.0% | |
| Q4 2024 | -2.6% | -4.2% | +51.1% | |
| Q3 2026 | -3.7% | +23.9% | +36.2% | |
| Q3 2024 | +1.6% | +7.0% | +37.8% | |
| Q2 2024 | +5.2% | +5.2% | +2.6% | |
| Q1 2024 | -3.4% | -10.3% | -78.1% | |
| Q4 2023 | -3.3% | -9.1% | -6.1% | |
| Q3 2023 | -7.9% | -5.9% | -31.7% | |
| Q2 2023 | -10.5% | +55.8% | +113.7% | |
| Q1 2023 | +0.0% | -8.6% | -68.6% | |
| Q4 2022 | -34.4% | -46.9% | -74.6% | |
| Q3 2022 | +0.0% | +0.0% | +12.0% | |
| Q2 2022 | +2.7% | -8.1% | -5.4% | |
| Q1 2022 | -9.2% | -11.8% | -17.1% | |
| Q4 2021 | -4.3% | -11.1% | -35.0% | |
| Q3 2021 | -6.8% | -0.7% | +5.4% | |
| Q2 2021 | -15.3% | -17.8% | -29.8% | |
| Q1 2021 | +15.2% | -9.6% | -38.2% | |
| Q3 2020 | +24.4% | +16.0% | +31.9% | |
| Q2 2020 | -10.5% | -21.1% | +321.1% | |
| Q1 2020 | +13.3% | -26.7% | +46.7% | |
| Q3 2019 | +7.3% | -2.4% | -4.9% | |
| Q2 2019 | -2.2% | -4.4% | -6.7% | |
| Q1 2019 | +4.0% | +9.3% | -10.7% | |
| Q1 2015 | +3.4% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q1 2013 | -1.9% | — | — | |
| Q3 2012 | -9.8% | — | — | |
| Q1 2010 | +1.8% | — | — | |
| Q1 2012 | +1.8% | — | — | |
| Q4 2011 | -3.0% | — | — | |
| Q3 2011 | +4.8% | — | — | |
| Q2 2010 | +3.4% | — | — | |
| Q4 2010 | +1.4% | — | — | |
| Q3 2010 | -1.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro